Indian NGO Challenges Patent For Roche’s Anti-HIV Valcyte
This article was originally published in PharmAsia News
Executive Summary
An Indian group has filed a challenge to the government's grant of a patent for Roche's Valcyte (valglanciclovir) drug for treating HIV. Roche received the patent last year from the Chennai patent office, but the challenge by the Delhi Network of Positive People said it was granted without hearing opposing arguments by two non-governmental organizations. The contention of the opposition is that the drug is a known compound, or at least no more than a new version of a known substance, and therefore does not justify a patent. Roche also holds patents on the drug in other countries. (Click here for more
You may also be interested in...
A Closer Look: India Patent Disputes Heat Up For Big Pharma
MUMBAI - Multinational pharmaceutical companies eyeing the growing Indian market may find themselves confronting a challenging patent environment during the next few years as public interest groups look to further intensify patent oppositions
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.